Tech Company Financing Transactions
Atalanta Therapeutics Funding Round
Atalanta Therapeutics closed a $75 million Series B funding round on 1/28/2025. Investors included EQT Life Sciences, Sanofi Ventures and Abrdn.
Transaction Overview
Company Name
Announced On
1/28/2025
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series B
Investors
EQT Life Sciences (Lead Investor)
Sanofi Ventures (Lead Investor)
F-Prime Capital (Stacie Weninger)
Proceeds Purpose
The company intends to use the funds to support Phase 1 clinical trials of its investigational RNAi therapies for KCNT1-related epilepsy and Huntington's disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6 Tide St. 2nd Floor
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Undisclosed
Website
Email Address
Overview
Atalanta was founded by world-leading experts in RNA interference to pioneer new treatment options for intractable neurodegenerative diseases. We take our name from the mythological Greek heroine Atalanta, a fierce huntress and, in some accounts, the only woman to sail with the Argonauts in their quest for the Golden Fleece.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alicia Secor
Chief Scientific Officer
Aimee Jackson
Vice President
Michele Keough
VP - Bus. Development
Gregory Miller
VP - General Counsel
Bart Newland
VP - Human Resources
Stephen Burke
VP - R & D
Daniel Curtis
Browse more venture capital transactions:
Prev: 1/28/2025: Tradeverifyd venture capital transaction
Next: 1/28/2025: Whizzo venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC transactions reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs